<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>EHP Financial Share News Feed - London South East</title>
    <link>http://www.lse.co.uk/</link>
    <description>EHP Financial Share News Feed - London South East</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 May 2013 20:04:52 GMT</lastBuildDate>
    <copyright>2007 London South East</copyright>
    <docs>http://www.lse.co.uk/rss/</docs>
    <ttl>15</ttl>
    <item>
      <title>BRIEF-Epistem says will raise about 4.3 mln stg via share placement</title>
      <description>
    LONDON, Dec 7 (Reuters) - Epistem Holdings PLC: 
    * Cash placing 
    * To raise about £4.3 million through a placing for cash of 793,398 new 
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=w7nbphvc0ynnmzy</link>
      <pubDate>Fri, 07 Dec 2012 13:19:22 GMT</pubDate>
    </item>
    <item>
      <title>RESEARCH ALERT-Peel Hunt raises Epistem target price</title>
      <description>
    Sept 25 (Reuters) - Epistem Holdings PLC: 
    * Peel Hunt raises Epistem target price to 750p from 600p; rating buy 
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=vmo6j997sz4q9zo</link>
      <pubDate>Tue, 25 Sep 2012 08:00:57 GMT</pubDate>
    </item>
    <item>
      <title>RESEARCH ALERT-Peel Hunt raises Epistem target price</title>
      <description>
    Aug 6 (Reuters) - Epistem Holdings PLC: 
    * Peel hunt raises target price to 600p from 515p; rating buy 
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=u8ld9rqmwfv1j0y</link>
      <pubDate>Mon, 06 Aug 2012 07:27:10 GMT</pubDate>
    </item>
    <item>
      <title>BRIEF-Epistem to raise 2.8 mln stg in placing</title>
      <description>
    LONDON, Nov 25 (Reuters) - Epistem Holdings PLC: 
    * To raise approximately £2.8 million before expenses through a placing of 793,398 shares at 1.5 pence per share 
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=o93dtbzmqf2o9zb</link>
      <pubDate>Fri, 25 Nov 2011 12:18:34 GMT</pubDate>
    </item>
    <item>
      <title>BRIEF-Epistem wins further long term funding from NIH project</title>
      <description>
    LONDON, Nov 3 (Reuters) - Epistem Holdings Plc: 
    * Awarded further long term funding for U.S. National Institutes of Health (NIH) biodefence programme 
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=mjqy6mmoh3xzbhg</link>
      <pubDate>Wed, 03 Nov 2010 07:29:51 GMT</pubDate>
    </item>
    <item>
      <title>BRIEF-Epistem raises 2.9 mln stg via placing</title>
      <description>
    LONDON, Nov 20 (Reuters) - Epistem Holdings Plc: 
    * £2.9M cash placing 
     ((London Equities Newsroom; +44 20 7542 7717)) 
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=kc8ors280xbjfon</link>
      <pubDate>Fri, 20 Nov 2009 08:47:11 GMT</pubDate>
    </item>
    <item>
      <title>UPDATE 2-Epistem at record high on Novartis research deal</title>
      <description>
    LONDON, March 2 (Reuters) - British biotech company Epistem  said on Monday it had signed a research and development deal with Novartis, securing it important future funding. 
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=ffjc7slxyqq1d62</link>
      <pubDate>Mon, 02 Mar 2009 11:15:16 GMT</pubDate>
    </item>
    <item>
      <title>EPISTEM SHARES UP 19 PCT AT RECORD HIGH OF 285P ON NOVARTIS R&amp;D DEAL</title>
      <description>
    For more information click on 
     
COPYRIGHT

Copyright Thomson Reuters 2009. All rights reserved.
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=ybejqq3cwbcldi9</link>
      <pubDate>Mon, 02 Mar 2009 08:26:10 GMT</pubDate>
    </item>
    <item>
      <title>UPDATE 1-Epistem clinches drug research deal with Novartis</title>
      <description>
    LONDON, March 2 (Reuters) - British biotech company Epistem  has signed a research and development deal with Novartis , securing it important future funding. 
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=oatlwsqyynu4kmk</link>
      <pubDate>Mon, 02 Mar 2009 07:34:01 GMT</pubDate>
    </item>
    <item>
      <title>EPISTEM HOLDINGS PLC - HAVE SIGNED A RESEARCH AND DEVELOPMENT COLLABORATION WITH NOVARTIS TO IDENTIFY NEW DRUG TARGETS</title>
      <description>
    For more see
COPYRIGHT

Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=3folpfj2powrr6e</link>
      <pubDate>Mon, 02 Mar 2009 07:27:01 GMT</pubDate>
    </item>
    <item>
      <title>BRIEF-Epistem signs research deal with Novartis</title>
      <description>
    LONDON, March 2 (Reuters) - Epistem Holdings Plc: 
    * Signs research and development deal with Novartis, gets $4 million upfront 
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=kosmwf0lg28sc20</link>
      <pubDate>Mon, 02 Mar 2009 07:16:40 GMT</pubDate>
    </item>
    <item>
      <title>EpiStem Holdings FY pretax loss widens; Q1 revenues 20 pct ahead year on year</title>
      <description>
    LONDON (Thomson Financial) - EpiStem Holdings Plc. said its full-year pretax loss widened but trading in the first three months of the new financial year has been strong, with 20 percent higher revenues compared with last year.
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=syomqt4cq6qtq9r</link>
      <pubDate>Mon, 06 Oct 2008 07:11:37 GMT</pubDate>
    </item>
    <item>
      <title>EpiStem says trading for year ended June 30 in line with market expectations</title>
      <description>
    LONDON (Thomson Financial) - EpiStem Holdings Plc. its trading for the financial year ended June 30 was in line with market expectations.
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=m9rlkg0qttwniip</link>
      <pubDate>Thu, 31 Jul 2008 10:38:40 GMT</pubDate>
    </item>
    <item>
      <title>EpiStem to provide pre-clinical testing services to Humanetics</title>
      <description>
    LONDON (Thomson Financial) - EpiStem Holdings Plc., the UK-based epithelial stem cell company, said it has been chosen by Humanetics Corporation of Minnesota, USA, to provide it with pre-clinical testing services for agents likely to protect the lining of the intestine from radiation damage.
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=yuc0pf2aywls2h1</link>
      <pubDate>Thu, 24 Jul 2008 08:55:28 GMT</pubDate>
    </item>
    <item>
      <title>EpiStem to provide preclinical efficacy testing to Exponential Biotherapies</title>
      <description>
    LONDON (Thomson Financial) - EpiStem Holdings Plc., the UK-based epithelial stem cell company, said it has been contracted by US-based Exponential Biotherapies Inc. to provide preclinical efficacy testing services.
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=mh132qr399pxuls</link>
      <pubDate>Tue, 01 Apr 2008 10:31:32 GMT</pubDate>
    </item>
    <item>
      <title>EpiStem Holdings H1 pretax loss widens; sees growth in biomarket business</title>
      <description>
    LONDON (Thomson Financial) - EpiStem Holdings PLC, the UK-based epithelial stem cell company said its first-half pretax loss widened but added that it will witness growth in its emerging biomarket business ahead.
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=zacfuy13vf9116s</link>
      <pubDate>Thu, 28 Feb 2008 08:26:33 GMT</pubDate>
    </item>
    <item>
      <title>Epistem and AstraZeneca complete preliminary trial for biomarker technology</title>
      <description>
    LONDON (Thomson Financial) - Epistem Holdings PLC and AstraZeneca have completed a preliminary trial for the company's human hair biomarker technology.
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=nmvo3yei0qragpz</link>
      <pubDate>Tue, 05 Feb 2008 12:16:56 GMT</pubDate>
    </item>
    <item>
      <title>EpiStem FY pretax loss widens; sees strong revenue growth in current year</title>
      <description>
    LONDON (Thomson Financial) - EpiStem Holdings PLC said its full-year pretax loss widened, but that it sees strong revenue for the current year on growing demand for its stem cell technology. 
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=70asgk49067ehqb</link>
      <pubDate>Wed, 10 Oct 2007 07:10:19 GMT</pubDate>
    </item>
    <item>
      <title>EpiStem completes first year of mucositis tests for potential biodefense drugs</title>
      <description>
    LONDON (Thomson Financial) - EpiStem Holdings PLC said it has completed the first year of efficacy-testing services for potential biodefense drugs combating mucositis, an inflammatory condition of the intestine linked with radiation sickness. 
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=rlzciyh5gpjn9pl</link>
      <pubDate>Thu, 20 Sep 2007 08:51:04 GMT</pubDate>
    </item>
    <item>
      <title>EpiStem says FY in line with company expectations, revenues up 50 pct</title>
      <description>
    LONDON (Thomson Financial) - EpiStem Holdings PLC said its results for the year ended June 30 are in line with management expectations and that revenues are up about 50 pct.
</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=oa0bau2xmrsxfbs</link>
      <pubDate>Tue, 31 Jul 2007 07:21:39 GMT</pubDate>
    </item>
    <item>
      <title>UK smallcap opening - EpiStem higher on AstraZeneca deal</title>
      <description>

    LONDON (Thomson Financial) - Good progress was seen in EpiStem, 4-1/2 pence better at 174-1/2, after the UK epithelial stem cell company said it has entered into feasibility studies with AstraZeneca to use its proprietary plucked hair biomarker technology to help guide preclinical and clinical</description>
      <link>http://www.lse.co.uk/ShareNews.asp?shareprice=EHP&amp;ArticleCode=2d1s5bm6gmdzzs0</link>
      <pubDate>Tue, 22 May 2007 07:00:37 GMT</pubDate>
    </item>
  </channel>
</rss>